FAQ on BioVaxys Technology Corp. and SpayVac-for-Wildlife Inc. Expanded License Agreement
Summary
What is the main topic of the press release?
The press release announces the expansion of the license agreement between BioVaxys Technology Corp. and SpayVac-for-Wildlife Inc. to include commercial aquaculture and the farm-raised fish market for SpayVac’s no-booster fertility-control vaccines.
Why is this expansion significant?
This expansion significantly increases SpayVac’s global revenue potential by opening up new markets for its contraceptive vaccines in aquaculture and farm-raised fish, offering a scalable and cost-effective solution for reproductive control.
How does SpayVac’s immunocontraceptive approach benefit aquaculture?
SpayVac’s approach requires only a single dose, offering producers a scalable and cost-effective solution for reproductive control in farmed fish, as an alternative to triploidy, a form of genetic manipulation commonly used in aquaculture to induce sterility.
Who is involved in this expanded license agreement?
BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (FRA: 5LB) and SpayVac-for-Wildlife Inc. are the parties involved in the expanded license agreement.
Where can I find more information about BioVaxys Technology Corp.?
More information about BioVaxys Technology Corp. can be found on their website at https://www.biovaxys.com.
What are the implications of this agreement for the global aquaculture sector?
The agreement opens the door to meaningful vaccine sales across the global aquaculture sector by providing a scalable and cost-effective solution for reproductive control in farmed fish.
How does SpayVac’s vaccine compare to triploidy?
SpayVac’s immunocontraceptive vaccine offers a simpler, more cost-effective alternative to triploidy, requiring only a single dose without the need for genetic manipulation.
Who made a statement regarding the expansion of the license agreement?
Thomas D’Orazio, CEO of SpayVac-for-Wildlife, commented on the substantial addressable market for SpayVac’s contraceptive vaccines in aquaculture.
Where can I view the full press release?
The full press release can be viewed at https://ibn.fm/Uu9L4.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 120538